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Background: Animal studies show that diets containing resistant starch (RS) at levels not achievable in the human
diet result in lower body weight and/or adiposity in rodents. We aimed to determine whether RS dose-dependently
reduces adiposity in obesity-prone (OP) and obesity-resistant (OR) rats.
Methods: Male Sprague–Dawley rats (n=120) were fed a moderate-fat, high-energy diet for 4 wk. Rats that gained
the most weight (40%) were classified as obesity-prone (OP) and obesity-resistant (OR) rats were the 40% that
gained the least weight. OP and OR rats were randomly allocated to one of six groups (n=8 for each phenotype).
One group was killed for baseline measurements, the other five groups were allocated to AIN-93 based diets that
contained 0, 4, 8, 12 and 16% RS (as high amylose maize starch) for 4 wk. These diets were matched for total
carbohydrate content. At 0, 4 and 7 wk from the start of the study insulin sensitivity was calculated by homeostasis
model assessment of insulin resistance (HOMA-IR) and adiposity was determined by dual-energy X-ray
absorptiometry (DXA). At 8 wk, rats were euthanized and fat pad weights, intestinal digesta short chain fatty acid
(SCFA) pools and plasma gut hormone levels were determined.
Results: Obesity prone rats gained less weight with 4, 12 and 16% RS compared to 0% RS, but the effect in OR animals
was significant only at 16% RS. Irrespective of phenotype, diets containing ≥8% RS reduced adiposity compared to 0% RS.
Energy intake decreased by 9.8 kJ/d for every 4% increase in RS. All diets containing RS increased total SCFA pools in the
caecum and lowered plasma GIP concentrations compared to the 0% RS, whereas plasma GLP-1 and PYY were increased
when the diet contained at least 8% RS. Insulin sensitivity was not affected by RS.
Conclusion: RS in amounts that could be potentially consumed by humans were effective in reducing adiposity and
weight gain in OP and OR rats, due in part to a reduction in energy intake, and changes in gut hormones and large bowel
carbohydrate fermentation.
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The global rise in Type 2 diabetes mellitus (T2DM)
prevalence in industrialised countries poses a very ser-
ious public health problem through its attendant compli-
cations. In Australia, as in many other countries, health
authorities are targeting primary and secondary preven-
tion strategies, in particular dietary change, as a means
of tackling the burgeoning T2DM epidemic [1]. As* Correspondence: damien.belobrajdic@csiro.au
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distribution, and reproduction in any mediumexcess adiposity (especially abdominal) is a strong risk
factor, approaches that reduce obesity are especially ef-
fective in lowering the prevalence of T2DM [2]. A dra-
matic reduction in risk of T2DM by at least 27% has
been consistently shown when people consume higher
levels of whole grain foods and cereal fibre [3]. Import-
antly, the data show that the metabolic health benefits
are independent of reductions in body weight [3].
Resistant starch (RS) is the fraction of dietary starch that
escapes digestion in the small intestine and passes into the
large bowel of healthy humans thereby contributing to
total dietary fibre intake [4]. The benefits of RS for guttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Composition of the diet (as fed)
Moderate fat Resistant starch
0% 4% 8% 12% 16%
Ingredients, g/kg
LAMS 1 215 530 400 270 130 0
HAMS 2 0 0 130 260 400 530
Casein 190 200 200 200 200 200
Maltodextrin10 75 0 0 0 0 0
Sucrose 290 100 100 100 100 100
Anhydrous milk fat 3 44.2 0 0 0 0 0
Sunflower seed oil 118 70 70 70 70 70
Wheat bran 0 50 50 50 50 50
α-cellulose 30 0 0 0 0 0
Vitamins 4 11 10 10 10 10 10
Minerals 4 40 35 35 35 35 35
L-cystine 3 3 3 3 3 3
Choline bitartrate 2.5 2.5 2.5 2.5 2.5 2.5
Energy5, kJ/g 17.9 15.7 15.1 14.5 13.8 13.2
1 LAMS, low amylose maize starch.
2 HAMS, high amylose maize starch was 1043 (National Starch, Australia), type
2 RS (RS2), composition per 100 g; 91 g total starch, 30 g resistant starch, 10.8
g moisture, 0.2 g fat, 0.8 g protein.
3Anhydrous milk fat, 99.9% fat (Fonterra, Mount Waverley, Australia).
4 Vitamin and mineral mix AIN-93G [10].
5 Energy content of the diets was calculated based on energy values provided
by the manufacturer for individual ingredients. An energy value of 10.45 kJ
was used for HAMS [11], as referred to by Aziz et al. [6].
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through large bowel microbial fermentation products, spe-
cifically short chain fatty acid (SCFA) [4]. Evidence for a
promising role for this particular type of fibre in the pre-
vention and management of T2DM is growing. RS can act
directly by reducing the glycaemic impact of a food by
displacing digestible carbohydrate [5], but other mechan-
isms seem to also contribute. Recently, Aziz et al. [6]
showed that in diet-induced obese rats, diets high in RS
(as high-amylose maize starch; HAMS) reduced body
weight gain (by 40%), fat pad weight and glycaemic re-
sponse, and increased insulin sensitivity compared to a
diet low in RS. Although these changes were dramatic
they were achieved at levels of RS that are not readily
achievable in the human diet. We have shown previously
that moderate to high levels of RS (as 20% HAMS providing
6% RS) reduced the body weight of healthy non-obese rats
compared to those fed a low-amylose control diet [7]. A
study by Higgins et al. [8] also showed that a diet containing
13% HAMS reduced adiposity but not weight regain in diet-
induced obese rats. Because dietary intakes of RS in indus-
trialised countries are low, it is important to establish
minimal levels of RS that elicit favourable metabolic effects
in obese and non-obese animals to assist in identifying ap-
propriate levels for human intervention trials.
This study aimed to determine whether there is a
dose-dependency or threshold effect of RS intake (as
HAMS) on body weight gain, adiposity and insulin sen-
sitivity in both obesity prone (OP) and obesity resistant
(OR) rats. The diet-induced obese rat model mimics
closely the major changes seen in obese humans, in par-
ticular whereby only a subset of the animals develop in-
sulin resistance and dyslipidemia [9]. The secondary
aims were to determine if RS fermentation in the large
bowel is associated with changes in plasma gut hormone
levels and whether they correlate with adiposity.
Methods
Rats and diets
Nine wk old, male Sprague–Dawley rats (Mean ± SE, 319 ±
5 g, n=120), were obtained from the Animal Resource
Centre, Western Australia. Rats were housed in groups of
3–4 rats in wire-bottomed cages in a room with controlled
heating and lighting (23°C with a 12-h light/dark cycle) and
had free access to food and water. After arrival, the rats were
adapted to a non-purified commercial diet for 1 wk. All pro-
cedures involving animals were approved by the Common-
wealth Scientific and Industrial Research Organisation Food
and Nutritional Sciences Animal Ethics Committee.
Pre resistant starch intervention
The rats were provided with a modified AIN-93G diet [10]
that contained a moderate amount of fat for 4 wk to induce
obesity (Table 1). After 3 wk the 40% of rats that had gainedthe most weight were classified as OP and the 40% of rats
that gained the least weight were classified as OR. After an-
other week, 16 rats were randomly selected (Baseline group
containing OP (n=8) and OR (n=8) rats) for baseline mea-
surements of body composition and intestinal digesta. The
remaining rats were allocated randomly to one of five diet-
ary treatment groups containing equal numbers (n=8) of OP
and OR rats.
Resistant starch intervention
The diets were based on AIN-93G formulation [10] and
contained increasing levels of HAMS (1043 National Starch,
Sydney, Australia) a type 2 RS (RS2) (Table 1). The HAMS
contained 91 g total starch, 8 g moisture, 0.2 g fat and 0.8 g
protein per 100 g. A low-amylose maize starch (Avon maize
starch, New Zealand Starch, Auckland, NZ) was used to bal-
ance starch levels in the diet and contained 87 g total starch,
0.7 g resistant starch, 11.9 g moisture, 0.1 g fat and 0.3 g
protein per 100g. Rats had free access to the powdered diets
which were fed for 4 wk. The amounts of RS in the diets as
fed were 0, 4, 8, 12 and 16 g/100 g of diet. These levels are
based on HAMS containing 30% RS as determined previ-
ously by us in pig and human studies [12,13].
At 0, 4 and 7 wk of the study the rats were deprived of
feed overnight (12 h) and anaesthetised using 40 mg/kg
Zoletil (Virvac, Sydney, Australia). Blood was taken from
a tail vein to determine glucose and insulin
Belobrajdic et al. Nutrition & Metabolism 2012, 9:93 Page 3 of 10
http://www.nutritionandmetabolism.com/content/9/1/93concentrations and body composition analysis was con-
ducted by dual energy X-ray absorptiometry (DXA);
Lunar Prodigy with Encore 2007 software version
11.40.004 (GE Medical Systems, Madison, WI). A whole
body scan was performed to measure body weight, bone
mineral content, body fat and lean mass. Body weight,
measured by DXA as the sum of lean mass, fat and bone
mineral content, was 1.1 ± 0.1% (n=120) lower than
body weight measured gravimetrically.
At 2 and 6 wk of the study, diet intake was measured by
isolating rats in individual cages for 48 h. The amount of
diet remaining at 24 and 48 h was weighed and average
daily diet intake calculated. Average daily gross energy in-
take was calculated by multiplying the average daily diet in-
take by the energy density of the diet. The amount of RS in
grams consumed by each rat per day for each diet was cal-
culated by multiplying the average daily food intake (in g)
for each rat by the amount of RS in the diet (in g per g). In
the final week of the study faecal samples were collected
from rats immediately after defecation and promptly fro-
zen at −20°C for fat analysis.
At the conclusion of the study rats were anesthetised
with 5% isoflurane in oxygen. Blood was collected from the
abdominal aorta, processed after 30 min to obtain EDTA
plasma and stored at −80°C until analysed. The major
organs and adipose tissue, including mesenteric, epididy-
mal, retroperitoneal and inguinal fat were removed and
weighed. Visceral weight was reported as the sum of mes-
enteric, epididymal and retroperitoneal fat pad weights.
The caecum and colon were weighed separately and their
contents removed and weighed. The pH of the digesta was
determined (Activon, Melbourne, Australia) and samples
stored at −20°C for SCFA analysis. The weight of the full
caecum was used to correct final body weight and weight
gain, as described previously [6], in order to account for
the increase in caecal tissue and digesta mass with increas-
ing RS in the diet.
Blood biochemistry
Plasma glucose, triglyceride and total cholesterol concen-
trations were measured using standard Roche enzymatic
kits (Roche Diagnostics Co) and plasma non-esterified
fatty acids (NEFA) were measured using a Randox kit.
Assays were conducted using a BM/Hitachi 902 Auto-
matic Analyzer. Fasting plasma insulin and non-fasted
GLP-1 (total) were analysed by ELISA (Millipore).
The concentrations of insulin, GIP, PYY and leptin in
non-fasted plasma collected at necropsy were determined
using a rat gut hormone multiplex kit (Millipore, St.
Charles, MO) according to manufacturer’s instructions.
Multianalyte profiling was performed on the Qiagen Liqui-
Chip 200 Workstation and fluorescence data were analysed
by using the Qiagen LiquiChip Analyzer Software (version
1.0.5). A sub-set of samples from each dietary treatmentgroup (n=8) were analysed in one run on one plate and the
mean intra-assay variability ranged from 8 to 14%.
The homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated from fasting glucose and insu-
lin levels and applying the following formula that has been
validated for use in rats [14]. HOMA-IR = (fasting plasma
glucose mg/dL x fasting plasma insulin μU/mL)/2,430).
Digesta and liver analyses
Faecal and caecal contents were distilled and analysed
for SCFA by gas chromatography, as described previ-
ously [15]. The total SCFA levels reported were the sum
of the major (acetate, propionate and butyrate) and
minor SCFA (isobutyric, isovaleric, valeric and caproic).
The fat content of liver and faeces was extracted by
the modified method of Folch et al. [16]. In brief, ap-
proximately 1 g of liver tissue and 0.5 g faeces were
freeze dried for 24 h then ground to a fine powder using
a mortar and pestle. The powder was acidified with 25%
HCl, homogenised and then extracted twice using 2:1
chloroform:methanol. The extracts were dried under ni-
trogen and weighed. Liver fat was expressed as a per-
centage of liver weight. Daily faecal fat excretion was
calculated by multiplying the percentage of faecal fat by
the daily faecal wet weight excreted in 24 h.
Statistical analyses
The data are presented as the arithmetic mean and SEM
for each treatment group. Growth rate, body compos-
ition data (as measured by DXA), and fasting glucose
data obtained during the pre-RS treatment phase and
the RS intervention were assessed using a repeated mea-
sures 2-way ANOVA. For the RS intervention, the data
were analysed as a randomised complete block design
with 2 x 5 factorial treatment structure using a 2-way
ANOVA. Change in fat pad weights and total body fat
mass were analysed using energy intake as a covariate.
Significant interactions between RS and phenotype were
analysed using pair-wise comparisons of simple main
effects and applying a Bonferroni adjustment for mul-
tiple comparisons. In the absence of an interaction, dif-
ference between treatments was assessed by a Tukey’s
post-hoc test. Standard multiple regression analysis was
used to estimate correlations between variables and en-
ergy intake data were analysed by standard linear regres-
sion. These analyses were performed using SPSS version
18.0 (SPSS Inc., Chicago Il USA). A value of P < 0.05
was taken as the criterion of significance.
Results
Pre resistant starch intervention
Prior to commencing the moderate fat diet OP rats were
heavier than OR rats (P<0.01) (Table 2). Thereafter, OP
rats gained 7% more weight (P<0.0001) and 1.6% more
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OP rats also consumed more food (OP; 22.2 ± 0.4, OR;
19.8 ± 0.3 g/d, P<0.0001) and energy per d (OP; 399 ± 7,
OR; 355 ± 6 kJ/d, P=0.0001) in comparison to the OR rats.
However, fasting blood glucose and insulin levels, and in-
sulin resistance, were all similar for both OP and OR rats
after consuming the moderate fat diet for 4 wk (Table 2).Resistant starch intervention
Diet, gross energy and RS intakes
The OP rats in comparison to OR rats consumed more
food (OP; 25.5 ± 0.5, OR; 23.9 ± 0.3 g/d, P<0.05) and en-
ergy per d (OP; 368 ± 8, OR; 345 ± 6 kJ/d, P=0.05). The
level of RS in the diet tended (P=0.076) to reduce energy
intake (Table 3). However, linear regression analysis
showed that for every 4% increase in the amount of RS in
the diet, energy intake decreased by 9.8 kJ/d (P < 0.01).
Average RS intakes were 0, 1.2, 2.5, 3.9 and 5.0 g/d for 0,
4, 8, 12 and 16% RS diets respectively.Body weight and composition
The effect of RS on body weight gain was dependent on
phenotype (P<0.05) (Figure 1). For OP rats, the addition of
4%, 12% or 16% RS to the diet reduced weight gain in com-
parison to the 0% RS diet, whereas in OR rats, weight gain
was only reduced by the 16% RS diet (Figure 1). RS did not
affect final body weight independent of the obesity pheno-
type (Table 3). However, there was a trend for RS to lower
final body weight corrected for caecum full weight
(P=0.06) (Table 3). Final body weight and corrected final
body weight were higher for the OP animals in comparison
to OR animals (Table 3).
The RS diets lowered adiposity regardless of whether ani-
mals were OP or OR. After 3 wk, a minimum of 8% RS
reduced total body fat in comparison to the 0% RS fed rats
(Figure 2). At 4 wk, there was less visceral fat in rats on diets
containing 8% or more RS (Figure 3). This reduction in vis-
ceral fat mass was similar for all visceral fat sites including
mesenteric fat, epididymal fat and retroperitoneal fat (dataTable 2 Change in body weight gain, body composition and
resistant rats after 4 wk on a moderate fat diet
Obesity resistant
wk 01 wk 41
Body weight, g 297 ± 4 366 ± 5
Fat mass, % 5.8 ± 0.3 10.5 ± 0.5
Bone mineral density, g/cm3 0.183 ± 0.001 0.207 ± 0.001
Fasting glucose, mmol/L 5.3 ± 0.1 6.3± 0.1
Fasting insulin3, pmol/L 94 ± 27 267 ± 48
HOMA-IR3 0.5 ± 0.1 1.8 ± 0.3
1 n=48 obesity-resistant, n=48 obesity-prone.
2 Percent change from 0 to 4 wk. Significant difference between obesity-resistant a
3 Fasting insulin and HOMA-IR were measured in a subset of rats; n=4 obesity resistnot shown). Visceral fat mass was also greater in OP (4.7 ±
0.2% body weight) than OR rats (3.8 ± 0.1% body weight)
(P<0.0001). Inguinal fat mass was reduced by diets con-
taining 4% or higher RS in comparison to the 0% RS group
(Figure 3). In addition, these effects of RS on reducing
total body fat, and visceral and subcutaneous fat depots
were maintained even when energy intake was included as
a covariate.
After 4 wk on the RS diets, rats fed 8% or more RS had
visceral and subcutaneous fat contents similar to the base-
line rats (visceral fat, 3.9 ± 0.2% body weight and subcuta-
neous fat 0.7 ± 0.06% body weight). In comparison to the
baseline group, the 0 and 4% RS group accumulated more
visceral (0% RS, 62%, P<0.0001; 4% RS, 37%, P<0.01) and
subcutaneous fat (0% RS, 67%, P<0.0001, 4% RS, 19%,
P<0.0001).
Lean tissue as a percentage of body weight was not
affected by the amount of RS added to the diets (data not
shown). Lean tissue of OR (11.8 ± 0.7%) and OP rats (12.3
± 0.7%) increased by similar amounts during the RS
intervention.
RS affected liver weight, independent of obesity pheno-
type. Liver weights of rats fed 8% (P<0.05) and 16% RS
(P<0.0001) were lighter than those of the 0% RS group
(Table 3). Hepatic lipid content was higher for OP rats in
comparison to OR rats, but was not affected by the
amount of RS in the diet (Table 3). However, the livers of
rats fed ≥ 0% RS tended to contain less lipid (6.5 ± 0.2%)
than the baseline group (7.6 ± 0.3%) (P=0.06). RS content
of the diet did not affect heart weight, spleen weight or
kidney weight (data not shown).Large bowel variables
The 4% RS group in comparison to the 0% RS group
increased colonic digesta weight, total SCFA pools and pH
(Table 4). In addition, the inclusion of a minimum of 8%
RS in the diet increased a number of general bowel health
endpoints, including caecal total SCFA pools, caecal digesta
weight and faecal output in comparison to the 0% RS dietserum biochemistry of obesity-prone and obesity-
Obesity prone
Δ (%)2 wk 01 wk 41 Δ (%)2
26 322 ± 4 427 ± 5 33 **
4.7 7.0 ± 0.3 13.3 ± 0.6 6.3 *
13.6 0.185 ± 0.001 0.216 ± 0.0001 17.4 **
20 5.5 ± 0.1 6.4 ± 0.1 18
210 141 ± 32 344 ± 56 250
300 0.9 ± 0.2 2.5 ± 0.5 280
nd obesity-prone rats is denoted by * P < 0.05, ** P < 0.0001.
ant and n=3 obesity prone.
Table 3 Diet and energy intakes, body weight, liver weight and fat content of obesity-prone and obesity-resistant rats
consuming diets with different levels of resistant starch1
Resistant starch (RS), % of diet weight Main Effects (P-value)
0% 4% 8% 12% 16% RS Phenotype RS x Phenotype
Gross energy intake2,3, kJ/d 378 ± 12 364 ± 7 355 ± 12 345 ± 12 338 ± 10 0.076 0.0187 0.857
Final body weight2,4, g 485 ± 15 465 ± 12 445 ± 18 474 ± 11 461 ± 14 0.136 0.00018 0.692
Final body weight corrected2,4,5, g 483 ± 15 462 ± 12 437 ± 18 467 ± 12 449 ± 13 0.06 0.00019 0.724
Liver wt2,4, %BW 3.19 ± 0.08 c 3.15 ± 0.03 bc 3.02 ± 0.05 ab 3.04 ± 0.05 bc 2.83 ± 0.07 a 0.0001 0.126 0.056
Liver fat content6, % 6.4 ± 0.4 6.4 ± 0.3 6.3 ± 0.1 6.5 ± 0.4 6.6 ± 0.4 0.764 0.01010 0.613
1 Values are means ± SEM. Labelled means without a common letter differ, P < 0.05.
2 n=8 obesity-prone and n=8 obesity-resistant rats.
3 Measured after rats were fed the RS diets for 2 wk.
4 Measured after rats were fed the RS diets for 4 wk.
5 Final body weight corrected = body weight – full caecum weight.
6 n=8 (n=4 obesity-prone and n=4 obesity-resistant rats per group).
7 Obesity-prone 368 ± 8 kJ/d, Obesity-resistant 345 ± 6 kJ/d.
8 Obesity-prone 502 ± 7 g, Obesity-resistant 445 ± 6 g.
9 Obesity-prone 497 ± 7 g, Obesity-resistant 441 ± 6 g.
10 Obesity-prone 7.0 ± 0.2%, Obesity-resistant 6.1 ± 0.2%.
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to the level of RS in the diet were also dependent on
phenotype. In OR rats caecal digesta weight reached a ma-
ximal level with 12% RS whereas in OP rats caecal digesta
weight was maximal at the highest level of RS (16%)
(Table 4).
The amount of fat excreted in faeces was not affected
by the addition of RS to the diet or the obesity pheno-
type (Table 4).*
Figure 1 Body weight gain in obesity-prone (●) and obesity-resistant
(RS) for 4 wk. Body weight gain is corrected body weight as calculated by
initial body weight. Values are expressed as mean ± SEM. There was a sign
difference in comparison to 0% RS is denoted by (*) for obesity prone rats
were comprised of a total of 16 animals; n=8 obesity prone and n=8 obesiInsulin sensitivity, lipids and gut hormones
The amount of RS in the diet or obesity phenotype did not
affect fasting plasma levels of glucose or insulin, or insulin
resistance as determined by HOMA-IR (Additional file 1:
Table S1).
The inclusion of 8% RS or more in the diet reduced
plasma triglyceride and total cholesterol concentrations in
comparison to the 0% RS group (Table 5). Plasma leptin
concentration was higher in OP than OR rats (P < 0.05)*
*
#
(○) Sprague Dawley rats fed differing levels of resistant starch
the following formula; (final body weight – full caecum weight) –
ificant interaction between RS and phenotype (P < 0.05). A significant







Figure 2 Change in body fat mass in Sprague Dawley rats fed differing levels of RS for 3 wk. Values are expressed as mean ± SEM.
Change in body fat mass was affected by RS (P <0.0001). Dietary treatment groups were comprised of a total of 16 animals; n=8 obesity-prone
and n=8 obesity-resistant.
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(P < 0.05) (Table 5). The addition of RS to the diets did
not affect plasma NEFA concentration.
Plasma gut hormone concentrations were affected by the
level of RS in the diet, but unaffected by phenotype
(Table 5). GLP-1 and PYY increased when a minimum of
8% RS was included in the diet (P < 0.05) whereas GIP
concentration was lower for all diets containing added RS
(P < 0.05) (Table 5). Caecal digesta SCFA pools were asso-
ciated with concentrations of plasma GLP-1 (r=0.317,
n=38, P < 0.005) and PYY (r=0.433, both n=38, P < 0.005)
and inversely associated with plasma GIP (r=−0.538, n=37,
P < 0.001). Plasma GLP-1 and PYY were inversely asso-
ciated with total body fat mass (GLP-1; r=−0.396, n=39,
P<0.01, PYY; r=−0.421, n=39, P < 0.01) and visceral fat
mass (GLP-1; r=−0.428, n=39, P < 0.01, PYY; r=−0.438,
n=39, P < 0.01). PYY was inversely associated with sub-
cutaneous fat mass (r=−0.308, n=38, P < 0.036), but GLP-1
was not (r=−0.224, n=36, P = 0.098).
Discussion
Animal studies consistently show that diets containing high
levels of RS (16%) reduce body weight gain and/or adiposity
in rodents [6,17,18]. Moderate levels of RS (4-6%) also
reduced weight gain in healthy rats [7] and adiposity during
weight regain in obese rats [8]. However, the effects ofmoderate to high RS levels in the diet on adiposity and
weight gain have not been examined in OP or OR rodents
without prior exposure to a weight loss diet. The present
study demonstrated clearly that dietary RS reduced body
weight gain, although not final body weight, and that the ef-
fect was dependent on the level of RS in the diet and on
the phenotype of the rats. When compared to 0% RS,
weight gain was significantly lower in OP rats when fed RS
at 4, 12 and 16% whereas in OR rats, weight gain was sig-
nificantly lower only when fed 16% RS. These differences
between obesity phenotype could be due to differences in
colonic fermentation. In support of this Zhou et al. [18]
demonstrated that RS did not reduce adiposity in genetic-
ally obese mice that were unable to ferment RS. Addition-
ally studies by Gordon and colleagues show that differences
in microbial populations between obese and lean indivi-
duals may explain the phenotypic differences [19] however
differences in energy intake may also account for this effect.
The current study demonstrated that the level of RS in the
diet necessary to reduce adiposity, was independent of the
obesity phenotype. Although OP rats fed 4% RS gained
less weight than rats on the 0% RS diet, visceral and sub-
cutaneous adipose tissue weights, total adiposity and en-
ergy intake did not differ. In humans replacement of 5.4%
of total dietary carbohydrate with RS (approximately 5 g










Figure 3 Visceral fat mass (A) and inguinal fat mass (B) in Sprague Dawley rats fed differing levels of resistant starch (RS) for 4 wk.
Values are expressed as mean ± SEM. Visceral fat mass was the sum of mesenteric, epididymal and retroperitoneal fat pad weights and was
affected by RS (P <0.0001) and phenotype (P <0.0001). Inguinal fat mass was only affected by RS (P <0.0001). Dietary treatment groups were
comprised of a total of 16 animals; n=8 obesity prone and n=8 obesity resistant.
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not affect body weight or fat storage in muscle, liver and
visceral depots in overweight/obese subjects [21]. The
higher dietary levels of RS (8%) used in the present study
lowered total body and visceral adipose tissue weight, aswell as plasma triglycerides, total cholesterol and leptin.
This level of RS intake, which equates to about 88 g/d for
a 75 kg human, would be difficult to achieve for most
adults [22]. However it is possible that lower amounts
(between 44 and 88 g/d for an adult) that could be readily
Table 4 Large intestinal tissue weights and fermentation parameters of obesity-prone and obesity-resistant rats
consuming diets with different levels of resistant starch for 4 wk1
Resistant starch, % of diet weight Main Effects (P-value)
0% 4% 8% 12% 16% RS Phenotype RS x Phenotype
Caecum
Digesta weight, g 0.015
Obesity-prone 1.7 ± 0.2 a 2.3 ± 0.3 a 6.4 ± 1.0 b 6.9 ± 1.0 b 11.5 ± 1.6 c
Obesity-resistant 1.5 ± 0.1 a 2.5 ± 0.5 ab 6.0 ± 0.7 b 9.5 ± 0.9 c 7.4 ± 1.3 bc
Total SCFA pool, mmol 169 ± 11 a 288 ± 43 ab 657 ± 83 bc 985 ± 150 c 1029 ± 150 c 0.0001 ns ns
Digesta pH 7.2 ± 0.1 c 6.8 ± 0.1 b 6.2 ± 0.1 a 6.0 ± 0.1 a 5.9 ± 0.1 a 0.0001 ns ns
Colon
Digesta weight, g 1.0 ± 0.1 a 1.9 ± 0.1 b 2.1 ± 0.2 bc 3.0 ± 0.2 d 3.2 ± 0.3 d 0.0001 ns ns
Total SCFA pool, mmol 69 ± 7 a 160 ± 14 b 184 ± 26 b 213 ± 20 b 215 ± 23 b 0.0001 0.0163 ns
Digesta pH 7.3 ± 0.1 c 6.3 ± 0.1 b 6.0 ± 0.1 ab 6.0 ± 0.1 ab 5.8 ± 0.1 a 0.0001 ns ns
Faeces
Faecal output g/d 1.7 ± 0.1 a 3.0 ± 0.2 ab 3.7 ± 0.3 b 5.8 ± 0.6 c 8.3 ± 0.5 d 0.0001 0.0284 ns
Faecal fat2, g/d 0.15 ± 0.02 0.09 ± 0.01 0.11 ± 0.02 0.09 ± 0.01 0.13 ± 0.01 ns ns ns
1 Values are means ± SEM. Labelled means without a common letter differ, P < 0.05. ns = not significant, P > 0.05. All dietary treatments consist of n=8 obesity-
prone and n=12 obesity-resistant rats.
2 n=8 (n=4 obesity-prone and n=4 obesity-resistant rats per group).
3 obesity-prone 188 ± 11 mmol, obesity-resistant 149 ± 11 mmol.
4 obesity-prone 4.9 ± 0.5 g/d, obesity-resistant 4.3 ± 0.2.
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consumption of foods high in RS, may elicit favourable
changes in adiposity. Furthermore, at these lower levels of
RS a greater reduction in adiposity may also be achieved
in a trial of longer duration.
The mechanisms by which RS reduces adiposity are likely
to involve a decrease in metabolisable energy intake and an
increase in fatty acid catabolism. In the current study gross
energy intake declined as the amount of RS increased in
the diet (16% RS reduced energy intake by 11%). An even
larger reduction in energy intake (16.4%) was reported for
rats consuming a high RS diet (equivalent to 16% RS) [6]
when total accumulative energy intake was measured daily
throughout the 4 wk trial rather than a 2-day measurementTable 5 Plasma lipids and gut hormones of obesity-prone and
different levels of resistant starch for 4 wk1
Resistant starch (RS), % of d
0% 4% 8%
Triglycerides2, mmol/L 1.4 ± 0.1 c 1.1 ± 0.1 bc 0.8 ± 0.1 ab
Free fatty acids2, mmol/L 0.30 ± 0.02 0.29 ± 0.02 0.32 ± 0.03
Total cholesterol2, mmol/L 1.8 ± 0.1 c 1.8± 0.1 bc 1.6 ± 0.1 ab
Leptin3, μg/L 14.7 ± 4.7 b 11.7 ± 1.1 ab 7.3 ± 4.5 a
GLP-13, pg/mL 29 ± 4 a 47 ± 4 ab 70 ± 7 bc
PYY3, pg/mL 71 ± 14 a 137 ± 11 ab 230 ± 30 bc
GIP3, pg/mL 372 ± 57 a 165 ± 29 b 134 ± 25 b
1 Values are means ± SEM. Labelled means without a common letter differ, P < 0.05
polypeptide Y, GIP; gastric inhibitory peptide.
2 n=16 (Obesity-prone; n=8, Obesity-resistant; n=8).
3 n=8 (Obesity-prone; n=4, Obesity-resistant; n=4).
4 obesity-prone 11.7 ± 1.7 μg/L, obesity-resistant 7.3 ± 1.1 μg/L.period used in the current study. In addition, studies that
matched the energy content of the control (0% RS) and RS
intervention diets, still resulted in a more effective lowering
of body fat than the control [17,18] which suggests that
mechanisms other than reducing energy intake may also
play a role in reducing adiposity. Fermentation of RS in the
large bowel has been proposed as a mechanism to explain
the increase in lipid oxidation [18,23]. SCFA, the major
products of RS fermentation, are absorbed by colonocytes
and enter the hepatic portal circulation where they can dir-
ectly regulate a variety of pathways involved in fatty acid
and cholesterol metabolism [24-26]. In particular, propion-
ate can reduce the incorporation of acetate into cholesterol
and inhibits fatty acid synthesis [27,28]. Additionally, aobesity-resistant rats after consuming diets with
iet weight Main Effects (P-value)
12% 16% RS Phenotype RS x Phenotype
0.9 ± 0.1 ab 0.7 ± 0.1 a 0.0001 ns ns
0.34 ± 0.04 0.30 ± 0.03 ns ns ns
1.5 ± 0.1 ab 1.5 ± 0.1 a 0.002 ns ns
8.3 ± 0.9 ab 5.3 ± 0.8 a 0.027 0.0424 ns
76 ± 6 bc 95 ± 23 c 0.0001 ns ns
222 ± 22 bc 297 ± 54 c 0.0001 ns ns
176 ± 52 b 81 ± 18 b 0.001 ns ns
. ns = not significant, P > 0.05. GLP-1; glucagon-like peptide −1, PYY;
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with lower serum cholesterol [29,30] but was not seen in
the current study. Although most SCFA produced in the
colon are metabolised by the liver small amounts enter the
systemic circulation [31,32] and there is growing evidence
that they may directly regulate adipogenesis and adipokine
release in adipose tissue mediated via G-protein coupled
receptors [25]. Fermentation of a single meal high in RS
(measured using breath hydrogen) was associated with a
reduction in plasma NEFA levels in healthy subjects [33].
This reduction in NEFA may be particularly effective in im-
proving insulin sensitivity in obese individuals and those
with T2DM as it would reduce fatty acid oxidation and
storage, increase muscle glucose uptake and oxidation, and
improve β-cell insulin secretory response to glucose [28].
However, in the current study it is not clear why RS did
not reduce plasma NEFA, but it may explain in part why
an improvement in insulin sensitivity was not seen. Add-
itionally, SCFA may modulate fat metabolism indirectly by
stimulating large bowel enteroendocrine cell production of
GLP-1 and PYY [29]. In the current study total SCFA
pools in caecal digesta were positively associated with
plasma concentrations of both hormones. GLP-1 and PYY
have been shown to be released into the blood in a sus-
tained day-long manner [30] and to act systemically on
white adipose tissue to regulate lipogenesis, lipolysis, fatty
acid release and adipocyte differentiation [31]. Addition-
ally, PYY can increase thermogenesis and energy expend-
iture, thereby reducing adiposity [32]. In support of this,
plasma GLP-1 and PYY levels explained 16 – 19% of the
change in total body fat mass and visceral fat mass. Fur-
thermore, diets containing added RS reduced plasma con-
centrations of GIP, a gut hormone known to promote
lipogenesis by stimulating adipose tissue blood flow, glu-
cose uptake and fatty acid re-esterification, and, as a con-
sequence, increased triglyceride deposition in abdominal
subcutaneous adipose tissue [33,34].
Foods containing RS elicit lower postprandial insulin
responses [34] and short-term consumption of RS (15–40
g/d) by healthy as well as overweight and obese subjects
improves insulin sensitivity [21,35,36]. Studies in rats also
show consistent positive effects for RS on postprandial gly-
cemic and insulinemic responses and whole body insulin
sensitivity [37]. Therefore, it was surprising in the current
study that resistant starch even at the highest level of diet-
ary inclusion did not improve insulin sensitivity of the rats.
It is possible that the duration of the moderate fat diet was
too short or that fasting levels of glucose and insulin were
not sensitive enough to discern changes in insulin sensitiv-
ity. Higgins et al. [38] showed that rats fed an amylopectin-
based diet (low in RS) developed insulin resistance (as
measured by an intravenous glucose tolerance test) after 3
mo of feeding whereas those on an amylose diet (high in
RS) developed insulin resistance after 6 mo. A feeding trialconsiderably longer than the 4 wk used in the current
study may be required to investigate the dose response
effects of resistant starch on improving insulin sensitivity.
The low fat background diet used in the present study is
not representative of the typical Western diet and may
have limited the impact of RS in improving insulin sensi-
tivity. Andersson et al. [39] showed that a low dietary fat
content ameliorated the negative effect of a high glycaemic
diet on insulin resistance. In our study the low level of
dietary fat was more effective in lowering hepatic fat levels
than feeding RS. However the length of the intervention
was only 4 wk and may have been too short to observe an
effect of RS on reducing heptic lipid content.
Conclusions
In summary, intakes of RS at levels that could be achieved
by humans were effective in reducing adiposity and weight
gain in rats, and also tended to reduce final body weight.
At the lower levels of dietary RS (4%) OP rats gained less
body weight in comparison to rats fed 0% RS, whereas for
OR rats a higher level of RS (16%) was required to limit
weight gain. This difference between phenotype is likely
explained by differences in colonic fermentation and
deserves further investigation. A role for RS fermentation
in reducing adiposity is supported by the positive relation-
ships between caecal digesta total SCFA pools and plasma
gut hormones (GLP-1 and PYY) that were inversely asso-
ciated with total body fat and visceral fat mass. Although
OP rats did not develop insulin resistance, the lowering of
plasma GIP by all dietary levels of RS was considerable
and deserves further investigation in animal models with
impaired insulin sensitivity.
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